Troubled Biotechs Roundup: Avigen, Jazz, Alfacell, Panacos
Unlike other troubled biotechs, Avigen is not cash-poor; however, it is not advancing its small pipeline and its largest investor has called foul.
Unlike other troubled biotechs, Avigen is not cash-poor; however, it is not advancing its small pipeline and its largest investor has called foul.